You are currently browsing the archives for 11 January 2018.
Displaying 1 - 2 of 2 entries.

Announced that the U today.

Celator Pharmaceuticals’ CPX-351 receives FDA Fast Track designation for secondary AML treatment Celator Pharmaceuticals, Inc. , a biopharmaceutical company that is transforming the research of mixture therapy and developing products to improve patient outcomes in cancers, announced that the U today www.tadora.biz .S. Food and Medication Administration granted Fast Track designation for CPX-351 for the treatment of elderly individuals with secondary Acute Myeloid Leukemia . The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs designed to treat serious or life-threatening conditions and that demonstrate the potential to handle unmet medical needs.

The 39th annual conference of the Society of Neuroscience drew some 30.

Researchers have demonstrated that memantine, a neuroprotective drug, may reduce the impulsive and addictive behavior associated with binge eating. The Boston University College of Medicine study, which appears on-line in Neuopsychopharmacology, also discovered that a particular area in the brain, the nucleus accumbens, which is in charge of addictive behaviors, facilitates the consequences of memantine. Binge-consuming disorder is usually a prevalent illness in the us, affecting more than 10 million people. It is characterized by periods of extreme uncontrolled consumption of meals, followed by uncomfortable feelings and fullness of self-disgust. New evidence indicates that adjustments in brain chemistry reflecting the addictive nature of bingeing may parallel medication and alcoholic beverages addiction.